Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 1-Year High – What’s Next?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s share price hit a new 52-week high on Tuesday . The stock traded as high as $139.00 and last traded at $138.27, with a volume of 30372 shares. The stock had previously closed at $136.69.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. TD Cowen cut their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Finally, Piper Sandler reiterated an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and an average price target of $180.33.

Jazz Pharmaceuticals Trading Up 2.2 %

The company has a 50 day moving average of $125.08 and a 200-day moving average of $118.24. The stock has a market cap of $8.45 billion, a price-to-earnings ratio of 19.62, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 5,053 shares of company stock valued at $617,442 in the last quarter. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at $25,000. Quadrant Capital Group LLC raised its position in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP grew its stake in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 183 shares in the last quarter. CoreFirst Bank & Trust purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $28,000. Finally, Allianz SE acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.